The Centre for Clinical Genomics (CCG) is pleased to announce its 84 gene Hereditary Cancer Program Panel is now available to patients across Canada. This panel replaced BRCA1/2 testing in British Columbia in October 2014.
AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CASR, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CTNNA1, DICER1, DIS3L2, EGFR, EPCAM, FH, FLCN, GATA2, GPC3, GREM1, HOXB13, HRAS, KIT, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1
MLPA for copy number changes is offered for BRCA1, BRCA2, MLH1 and MSH2 upon request.
In British Columbia: Referrals for this assay must be requested through the BC Cancer Agency Hereditary Cancer Program.
Outside British Columbia: please contact us for details and requisition forms.
The current turnaround time is 8 weeks. A list of ACMG 1, 2, and 3 variants with clinical interpretation will be reported by the Cancer Genetics Laboratory.
We are offering the 84 gene panel at the same cost as simply testing BRCA1/2. Please contact us for further details.
Variants in exons 12 and 15 of PMS2 are not reported.
The development of our next-generation sequencing assay is described in Bosdet et al. 2013.